<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27564" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Posttransplant Lymphoproliferative Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Samant</surname>
            <given-names>Hrishikesh</given-names>
          </name>
          <aff>Ochsner Multiorgan Transplant Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaitla</surname>
            <given-names>Pradeep</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kothadia</surname>
            <given-names>Jiten P.</given-names>
          </name>
          <aff>University of Tennessee Health Science Center, James D. Eason Transplant Institute</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hrishikesh Samant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pradeep Vaitla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jiten Kothadia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27564.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Post-transplant lymphoproliferative disorder (PTLD) is a well-known, life-threatening complication of organ transplantation, predominantly occurring after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). The majority of the cases of PTLD are associated with Epstein-Barr virus (EBV) and occur within the first posttransplant year. In planning for and in the years subsequent to a transplant, it is essential to consider the timeline and to consider whether trying to prevent certain complications such as transplant rejection via utilization of immunosuppressive agents outweighs the potential risk of infectious complications and the risk of PTLD. High-dose immunosuppression is associated with a higher risk of PTLD. The clinical presentation of PTLD can be highly variable ranging from localized to disseminated and can imitate benign conditions. Consequently, a high degree of clinical attention is crucial for early diagnosis and prompt treatment. This activity reviews the evaluation and management of post-transplant lymphoproliferative disorders and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at high risk for post-transplant lymphoproliferative disorder.</p></list-item><list-item><p>Explain how to weigh the risks and benefits of immunosuppressive agents, which may decrease risk of complications such as transplant rejection while simultaneously increasing risk of complications such as post-transplant lymphoproliferative disorder and infections.</p></list-item><list-item><p>Describe how to manage a patient with post-transplant lymphoproliferative disorder.</p></list-item><list-item><p>Outline the importance of enhancing care coordination among the interprofessional team to ensure proper evaluation and management of post-transplant lymphoproliferative disorder.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27564&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27564">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27564.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Post-transplant lymphoproliferative disorder (PTLD) is a well-known, life-threatening complication after organ transplantation, predominantly following solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). The majority of the cases of PTLD are associated with Epstein-Barr virus (EBV), and it occurs within the first posttransplant year. In the transplant setting, it is essential to consider the timeline following surgery and initiation of immunosuppression when considering infectious complications. High-dose immunosuppression is associated with a higher risk of PTLD. The clinical presentation of PTLD can be highly variable ranging from localized to disseminated disease, and it can imitate benign conditions. Consequently, a high degree of clinical suspicion is critical for early diagnosis and prompt treatment.<xref ref-type="bibr" rid="article-27564.r1">[1]</xref><xref ref-type="bibr" rid="article-27564.r2">[2]</xref><xref ref-type="bibr" rid="article-27564.r3">[3]</xref><xref ref-type="bibr" rid="article-27564.r4">[4]</xref><xref ref-type="bibr" rid="article-27564.r5">[5]</xref></p>
      </sec>
      <sec id="article-27564.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>PTLD is a proliferative B-cell disorder that is associated with the Epstein-Barr virus (EBV).&#x000a0;It can be acquired either as a result of primary infection (frequently), from the donor or environmental exposure. EBV-negative PTLD occurs in approximately 23% of patients. Solid organ transplant recipients are more commonly affected when compared to recipients of a hematopoietic stem cell transplant.</p>
      </sec>
      <sec id="article-27564.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of PTLD is variable, and it depends mainly on the type of organ transplant received, and immunosuppression used. The reported incidence of PTLD is between 2% to 20%, with a greater number of cases in patients who receive a solid organ transplant compared to allogeneic stem cell transplant recipients. The most important risk factors for PTLD include transplantation status (donor EBV-seropositive/recipient EBV-seronegative), ongoing immunosuppressive therapy, duration of immunosuppression, and status of EBV infection. Most described cases of PTLD arise in the setting of Epstein-Barr Virus (EBV) seropositivity and reactivation from latent B-cells, as a consequence of immune-suppression. Primary EBV infection occurs when an EBV-seronegative recipient gets an allograft from an EBV-seropositive donor (D+/R-), is known as the most significant risk factor for developing PTLD. Thus, higher rates of PTLD have been reported in pediatric than adult transplant recipients. A higher rate of PTLD is observed in the patients receiving heart, lung, small bowel transplant, or combined heart-lung transplant. The reason for these differences is partly due to the need for a higher dose of immunosuppression medications to prevent allografts' rejection.</p>
      </sec>
      <sec id="article-27564.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The majority of cases of PTLD are caused by EBV that is a herpes virus infecting up to 95% of the adult population. Primary infection with EBV in immunocompetent adult patients usually results in self-limiting illness without significant complications. However, once EBV infection occurs, either the virus remains latent in B-cell lymphocytes by the transformation of the cell expressing partial EBV genome, or it results in viral replication and B-cell lysis. In the immunocompetent patient, B-cell proliferation is controlled by cytotoxic T-cells while in an immunocompromised patient unchecked B-cell activation and continuous proliferation leads to PTLD.</p>
      </sec>
      <sec id="article-27564.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Only a histopathologic analysis of the tumor can determine the definite diagnosis of PTLD. The diagnosis is based on&#x000a0; the World Health Organization (WHO) classification and includes the following 4 main categories:</p>
        <list list-type="order">
          <list-item>
            <p>Monomorphic PTLD</p>
          </list-item>
          <list-item>
            <p>Polymorphic PTLD</p>
          </list-item>
          <list-item>
            <p>Early lesions</p>
          </list-item>
          <list-item>
            <p>Classic Hodgkin lymphoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27564.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical manifestations are heterogeneous, non-specific, and highly variable. PTLD can present as a localized or disseminated disease. Malaise, fatigue, fever, and a mononucleosis-like picture are some presenting features of PTLD. B-symptoms of fever, night sweats, and weight loss, as well as lymphadenopathy, are also frequent manifestations. PTLD develops rapidly and may cause compressive symptoms near the tumor site. Patients who are high-risk (EBV IgG Donor+/Recipient-) are generally noted to be at risk for developing PTLD of the transplanted graft causing a decline in organ function. It may be the only presenting symptom. The high index of suspicion for PTLD is necessary given highly variable presentation also rising EBV PCR in post-transplant recipient raises the possibility of PTLD.</p>
      </sec>
      <sec id="article-27564.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Besides a detailed history and physical examination of patients whom PTLD is considered, the investigations include:</p>
        <list list-type="order">
          <list-item>
            <p>Complete blood cell count (CBC) to evaluate unexplained anemia, thrombocytopenia or leukopenia</p>
          </list-item>
          <list-item>
            <p>Comprehensive chemistry panel</p>
          </list-item>
          <list-item>
            <p>Lactate dehydrogenase (LDH) to evaluate for tumor lysis syndrome.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urine analysis for Monoclonal protein, hyperuricemia</p>
          </list-item>
          <list-item>
            <p>EBV Status of recipient and donor</p>
          </list-item>
          <list-item>
            <p>Epstein-Barr virus (EBV) testes: EBV IgM, EBV IgG, EBV viral load (PCR). Also, serial EBV quantitative PCR measurement (that is rising) is more important and valuable than single positive EBV quantitative PCR. Negative EBV PCR does not exclude the possibility of PTLD.</p>
          </list-item>
          <list-item>
            <p>Radiological studies include computed tomography (CT), magnetic resonance imaging (MRI), and positive positron emission tomography (PET) scanning to evaluate spread.</p>
          </list-item>
          <list-item>
            <p>Lumbar puncture with cerebral spinal fluid (CSF) analysis (EBV PCR in CSF fluid) in patients with PTLD with CNS involvement</p>
          </list-item>
        </list>
        <p>Histopathologic examination of the tumor can only determine the definitive diagnosis.<xref ref-type="bibr" rid="article-27564.r6">[6]</xref><xref ref-type="bibr" rid="article-27564.r7">[7]</xref><xref ref-type="bibr" rid="article-27564.r8">[8]</xref></p>
      </sec>
      <sec id="article-27564.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment&#x000a0;strategies for PTLD are different from the management of lymphoproliferative disorders in immunocompetent patients. The mainstay of the management strategy includes the reduction of immunosuppression, surgical excision of the localized lesion, radiation therapy, rituximab monotherapy, immunochemotherapy, chemotherapy, stem-cell transplantation, and immunotherapy.<xref ref-type="bibr" rid="article-27564.r9">[9]</xref><xref ref-type="bibr" rid="article-27564.r10">[10]</xref><xref ref-type="bibr" rid="article-27564.r11">[11]</xref></p>
        <p>
<italic toggle="yes">
<bold>Reduction of Immunosuppression</bold>
</italic>
</p>
        <p>The initial management of PTLD is to reduce immunosuppression to restore cellular immunity without compromising allograft function. Reduction of the immunosuppression strategy should include at least 50% reduction calcineurin inhibitors (cyclosporine or tacrolimus) and discontinuation of antimetabolic agents such as azathioprine or mycophenolate mofetil (MMF).</p>
        <p>
<italic toggle="yes">
<bold>Rituximab</bold>
</italic>
</p>
        <p>Rituximab is a monoclonal anti-CD20 antibody. It is a standard of care in patients that do not respond adequately to reduced Immunosuppression. Rituximab can be administered as a single agent after the reduction of immunosuppression medications or in combination with chemotherapy (concurrently or sequentially). In the PTLD-1 study, the complete treatment response rate was around 25% after standard induction plus four courses of rituximab every 21 days. The primary side effects of rituximab include infusion reactions and increased risk of infections due to neutropenia. Also increased risk of hepatitis B reactivation in patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc) should be kept in mind.&#x000a0;</p>
        <p>
<italic toggle="yes">
<bold>Chemoimmunotherapy</bold>
</italic>
</p>
        <p>Chemotherapy is indicated in patients who have not had an adequate response to reduced immunosuppression and rituximab. It is usually administered in combination with rituximab for patients with CD20+ PTLD. &#x000a0;R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is commonly used in chemotherapy regimen for most patients with PTLD.</p>
        <p>
<italic toggle="yes">
<bold>Radiation Therapy</bold>
</italic>
</p>
        <p>Radiation therapy is used for patients with localized disease and those with central nervous system (CNS) involvement either alone or in combination.</p>
        <p>
<italic toggle="yes">
<bold>Adoptive Immunotherapy</bold>
</italic>
</p>
        <p>Adoptive Immunotherapy uses EBV-specific cytotoxic T lymphocytes (EBV-CTLs) or donor lymphocyte infusion (DLI) to induce a robust EBV-specific cellular immune response in patients with EBV-associated PTLD. &#x000a0;However, adoptive immunotherapy is associated with a high risk of developing acute and chronic graft-versus-host disease (GVHD).</p>
      </sec>
      <sec id="article-27564.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Given the highly variable presentation of PTLD differential diagnosis should broadly be&#x000a0;considered depending upon the patient's clinical presentation. Rejection of allograft organ (in the case of graft involvement), opportunistic infections, and common infectious etiology should be considered in the differential diagnosis.</p>
      </sec>
      <sec id="article-27564.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>With the introduction of rituximab, a monoclonal anti-CD20 antibody, and lymphoma-specific treatment regimens the overall prognosis for patients with PTLD has improved. In an international multicenter, open-label trial, sequential treatment with rituximab followed by CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, 53 of 59 patients had a complete or partial response, of which 40 patients had a complete response.<xref ref-type="bibr" rid="article-27564.r12">[12]</xref> Different prognostic scores have been published for PTLD but lack validity given small sample size, heterogeneous patient population, and treatment protocol used. The International Prognostic Index (IPI) is the commonly used prognostic index derived from five variables: age, stage, lactate dehydrogenase level, performance status, and the number of extranodal sites. Retransplantation after treatment of &#x000a0;PTLD is possible but is advised to wait at least one year after treatment for PTLD.<xref ref-type="bibr" rid="article-27564.r13">[13]</xref></p>
      </sec>
      <sec id="article-27564.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>PTLD is one of the severe complications of transplantation. The better understanding of the pathophysiology of PTLD, improvements in immunosuppressive strategies for solid organ transplantation, advances in the diagnosis and treatment of PTLD have led to improved clinical outcomes and overall prognosis for patients with PTLD.</p>
      </sec>
      <sec id="article-27564.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of PTLD require a multi-professional team of oncologists, radiation specialists, hematologists, surgeons, nurse practitioners, and primary care providers.&#x000a0;</p>
        <p>Treatment&#x000a0;strategies for PTLD are different from the management of lymphoproliferative disorders in immunocompetent patients. The mainstay of the management strategy includes a reduction in immunosuppression followed by surgical excision of the localized lesion, radiation therapy, rituximab monotherapy, immunochemotherapy, chemotherapy, stem-cell transplantation, and immunotherapy.</p>
        <p>The better understanding of the pathophysiology of PTLD, improvements in immunosuppressive strategies for solid organ transplantation, advances in the diagnosis and treatment of PTLD have led to improved clinical outcomes and overall prognosis for patients with PTLD.<xref ref-type="bibr" rid="article-27564.r14">[14]</xref></p>
      </sec>
      <sec id="article-27564.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27564&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27564">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/posttransplant-lymphoproliferative-disorders/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27564">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27564/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27564">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27564.s15">
        <title>References</title>
        <ref id="article-27564.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mizuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayasaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iizawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanemura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuriyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Azumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kishiwada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sakurai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Isaji</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>De Novo Malignancy Following Adult-to-Adult Living Donor Liver Transplantation Focusing on Posttransplantation Lymphoproliferative Disorder.</article-title>
            <source>Transplant Proc</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>2699</fpage>
            <page-range>2699-2704</page-range>
            <pub-id pub-id-type="pmid">30401380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dharnidharka</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive review of post-organ transplant hematologic cancers.</article-title>
            <source>Am J Transplant</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>537</fpage>
            <page-range>537-549</page-range>
            <pub-id pub-id-type="pmid">29178667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elserwy</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Lotfy</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Fouda</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Donia</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Mashaly</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Abuelmagd</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Abouelenein</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Bakr</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Postrenal transplant malignancy: Incidence, risk factors, and prognosis.</article-title>
            <source>Saudi J Kidney Dis Transpl</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>579</fpage>
            <page-range>579-588</page-range>
            <pub-id pub-id-type="pmid">28540896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ruthazer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Evens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>684</fpage>
            <page-range>684-692.e3</page-range>
            <pub-id pub-id-type="pmid">27771291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trusson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Serre</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Szwarc</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brunot</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Garrigue</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanouni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cartron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mourad</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients.</article-title>
            <source>Transplant Proc</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>1927</fpage>
            <page-range>1927-33</page-range>
            <pub-id pub-id-type="pmid">27569924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luskin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Heil</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stadtmauer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Vonderheide</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Bagg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heitjan</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Reshef</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.</article-title>
            <source>Am J Transplant</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>2665</fpage>
            <page-range>2665-73</page-range>
            <pub-id pub-id-type="pmid">25988622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gifford</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation.</article-title>
            <source>Intern Med J</source>
            <year>2015</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>583</fpage>
            <page-range>583-6</page-range>
            <pub-id pub-id-type="pmid">25955465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uemura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takemasa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mizushima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Doki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of perforated gastrointestinal posttransplantation lymphoproliferative disorder after heart transplantation.</article-title>
            <source>Int Surg</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>358</fpage>
            <page-range>358-64</page-range>
            <pub-id pub-id-type="pmid">25692442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varnous</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deback</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Golmard</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>857</fpage>
            <page-range>857-66</page-range>
            <pub-id pub-id-type="pmid">24666832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coupes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Vallely</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Picton</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus infection in adult renal transplant recipients.</article-title>
            <source>Am J Transplant</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>1619</fpage>
            <page-range>1619-29</page-range>
            <pub-id pub-id-type="pmid">24815922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimmermann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trappe</surname>
                <given-names>RU</given-names>
              </name>
            </person-group>
            <article-title>EBV and posttransplantation lymphoproliferative disease: what to do?</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>95</fpage>
            <page-range>95-102</page-range>
            <pub-id pub-id-type="pmid">24319169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trappe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mollee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sender</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reinke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Neuhaus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lehmkuhl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Horst</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jaccard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leith&#x000e4;user</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Anagnostopoulos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Raphael</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riess</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Choquet</surname>
                <given-names>S</given-names>
              </name>
              <collab>German PTLD Study Group</collab>
              <collab>European PTLD Network</collab>
            </person-group>
            <article-title>Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-206</page-range>
            <pub-id pub-id-type="pmid">22173060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cherikh</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Pavlakis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hanto</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis.</article-title>
            <source>Am J Transplant</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>2743</fpage>
            <page-range>2743-9</page-range>
            <pub-id pub-id-type="pmid">17049062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27564.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muchtar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gurion</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenblat</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bakal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shpilberg</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.</article-title>
            <source>Transplantation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>96</volume>
            <issue>7</issue>
            <fpage>657</fpage>
            <page-range>657-63</page-range>
            <pub-id pub-id-type="pmid">23823652</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
